Literature DB >> 3675876

Hepatic or splenic targeting of carrier erythrocytes: a murine model.

E Zocchi1, L Guida, U Benatti, M Canepa, L Borgiani, T Zanin, A De Flora.   

Abstract

Carrier mouse erythrocytes, i.e., red cells, subjected to a dialysis technique involving transient hypotonic hemolysis and isotonic resealing were treated in vitro in three different ways: (a) energy depletion by exposure for 90 min at 42 degrees C; (b) desialylation by incubation with neuroaminidase; and (c) oxidative stress by incubation with H2O2 and NaN3. Procedure (c) afforded maximal damage, as shown by analysis of biochemical properties of the treated erythrocytes. Reinfusion in mice of the variously manipulated erythrocytes following their 51Cr labeling showed extensive fragilization as indicated by rapid clearance of radioactivity from the circulation. Moreover, both the energy-depleted and the neuraminidase-treated erythrocytes showed a preferential liver uptake, reaching 50 and 75%, respectively, within 2 h. On the other hand, exposure of erythrocytes to the oxidant stress triggered a largely splenic removal, accounting for almost 40% of the reinjected cells within 4 h. Transmission electron microscopy of liver from mice receiving energy-depleted erythrocytes demonstrated remarkable erythrocyte congestion within the sinusoids, followed by hyperactivity of Kupffer cells and by subsequent thickening of the perisinusoidal Disse space. Concomitantly, levels of serum transaminase activities were moderately increased. Each of the three procedures of manipulation of carrier erythrocytes may prove applicable under conditions where selective targeting of erythrocyte-encapsulated chemicals and drugs to either the liver or the spleen has to be achieved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3675876

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  6 in total

1.  Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes.

Authors:  A De Flora; E Zocchi; L Guida; C Polvani; U Benatti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

2.  Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model.

Authors:  E Zocchi; M Tonetti; C Polvani; L Guida; U Benatti; A De Flora
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

Review 3.  Carrier erythrocytes. Clinical pharmacokinetic considerations.

Authors:  M Tonetti; A De Flora
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 4.  Drug-loaded erythrocytes: on the road toward marketing approval.

Authors:  Vanessa Bourgeaux; José M Lanao; Bridget E Bax; Yann Godfrin
Journal:  Drug Des Devel Ther       Date:  2016-02-11       Impact factor: 4.162

5.  18F-fluorodeoxyglucose positron emission tomography-computed tomography for assessing organ distribution of stressed red blood cells in mice.

Authors:  Wen-Yu Yin; Jiao Yuan; Zhi-Min Zhang; Cheng Mei; Wei Xu; Yong-Xiang Tang; Fang Peng; Ning Li
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

6.  On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver.

Authors:  Igor Theurl; Ingo Hilgendorf; Manfred Nairz; Piotr Tymoszuk; David Haschka; Malte Asshoff; Shun He; Louisa M S Gerhardt; Tobias A W Holderried; Markus Seifert; Sieghart Sopper; Ashley M Fenn; Atsushi Anzai; Sara Rattik; Cameron McAlpine; Milan Theurl; Peter Wieghofer; Yoshiko Iwamoto; Georg F Weber; Nina K Harder; Benjamin G Chousterman; Tara L Arvedson; Mary McKee; Fudi Wang; Oliver M D Lutz; Emanuele Rezoagli; Jodie L Babitt; Lorenzo Berra; Marco Prinz; Matthias Nahrendorf; Guenter Weiss; Ralph Weissleder; Herbert Y Lin; Filip K Swirski
Journal:  Nat Med       Date:  2016-07-18       Impact factor: 53.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.